Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Intervalo de año de publicación
1.
Rev Med Chil ; 136(1): 7-12, 2008 Jan.
Artículo en Español | MEDLINE | ID: mdl-18483648

RESUMEN

BACKGROUND: Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and beta2-microglobulin. AIM: To compare survival of patients with MM treated in six medical centers in Chile according to the D&S system and the new ISS. MATERIAL AND METHODS: Retrospective analysis of demographic information, clinical features and survival rate of patients treated between 1998 and 2002, and grouped according to both systems. RESULTS: Information of 81 patients aged 38 to 90 years (43 women) was retrieved. According D&S system 11% were in stage I 12% in stage II and 73% in stage III According to ISS, 34% were in stage I 35% in stage II and 31% in stage III Median of survival of all patients was 32 months. Both staging systems had a prognostic value. However, median survival for the three stages of the ISS system was significantly different (67, 29 and 14 months in stages III and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS, had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages II and III of ISS the presence of renal failure was associated with a non significantly different lower survival. CONCLUSIONS: The ISS is a simple and effective grouping method for patients with MM, that predicts survival. The presence of renal insufficiency might identify a subgroup of patients included in stages II and III of ISS with a higher mortality.


Asunto(s)
Mieloma Múltiple/patología , Estadificación de Neoplasias/métodos , Adulto , Anciano , Anciano de 80 o más Años , Chile/epidemiología , Métodos Epidemiológicos , Femenino , Humanos , Fallo Renal Crónico/complicaciones , Masculino , Persona de Mediana Edad , Mieloma Múltiple/mortalidad , Pronóstico
2.
Rev. méd. Chile ; 136(1): 7-12, ene. 2008. ilus, tab
Artículo en Español | LILACS | ID: lil-483214

RESUMEN

Background: Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and betaZ-microglobulin. Aim: To compare survival of patients with MM treated in six medical centers in Chile according to the D&S system and the new ISS. Material and methods: Retrospective analysis of demographic information, clinical features and survival rate of patients treated between 1998 and 2002, and grouped according to both systems. Results: Information of 81 patients aged 38 to 90 years (43 women) was retrieved. According D&S system 11 percent were in stage I 12 percent in stage II and 73 percent in stage III According to ISS, 34 percent were in stage I 35 percent in stage II and 31 percent in stage III Median of survival of all patients was 32 months. Both staging systems had a prognostic value. However, median survival for the three stages of the ISS system was significantly different (67, 29 and 14 months in stages III and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS, had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages II and III of ISS the presence of renal failure was associated with a non significantly different lower survival. Conclusions: The ISS is a simple and effective grouping method for patients with MM, that predicts survival. The presence of renal insufficiency might identify a subgroup of patients included in stages II and III of ISS with a higher mortality.


Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/patología , Estadificación de Neoplasias/métodos , Chile/epidemiología , Métodos Epidemiológicos , Fallo Renal Crónico/complicaciones , Mieloma Múltiple/mortalidad , Pronóstico
3.
Rev Med Chil ; 135(9): 1111-7, 2007 Sep.
Artículo en Español | MEDLINE | ID: mdl-18064364

RESUMEN

BACKGROUND: Mortality rate records are the only data available in Chile about the prognosis of patients with multiple myeloma (MM). AIM: To characterize clinical features, survival rate and factors related to mortality in cases with MM treated in six large medical centers in Chile. MATERIAL AND METHOD: Retrospective analysis of demographic data, clinical features and survival rate records of patients with MM, collected between 1998 and 2002. Survival curves were generated and a multivariate analysis of factors associated to early mortality was carried out. RESULTS: Data from 245 patients aged 38 to 95 years (129 women) was collected. Fifty two percent had an IgG myeloma, 25% had and IgA and 6.1% had light chains myeloma. According to Durie and Salmon staging system, 8,2% were in Stage 112.6% in Stage II, 60.5% in Stage III and in 18.8% the information about staging was not available. Fifty percent had an hemoglobin level below 10 g/dL, 30% had a serum creatinine over 2 mg/dL and 28% had a serum calcium level over 10.5 mg/dL. Median survival was 33 months. Twenty percent of patients died within the first six months after diagnosis (early mortality). Predictive factors for early mortality were male sex, thrombocytopenia, anemia, renal failure, hypercalcemia, a beta2-microglobulin >5.5 mg/L and a serum albumin level <3.5 g/dL. There was a correlation between the number of bad prognosis factors present and the probability of early mortality. CONCLUSIONS: This group of Chilean patients with MM presented a short survival time, and 20% died within the first six months after diagnosis. More than a half of cases were diagnosed at an advanced stage (Durie and Salmon Stage III). Several factors were associated to early mortality, two of which (beta 2-microglobulin and serum albumin), are included in the new International Staging System for MM.


Asunto(s)
Mieloma Múltiple/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Anemia/complicaciones , Chile/epidemiología , Métodos Epidemiológicos , Femenino , Humanos , Hipercalcemia/complicaciones , Masculino , Persona de Mediana Edad , Mieloma Múltiple/inmunología , Mieloma Múltiple/patología , Estadificación de Neoplasias , Pronóstico , Insuficiencia Renal/complicaciones , Albúmina Sérica/análisis , Factores Sexuales , Trombocitopenia/complicaciones , Factores de Tiempo , Microglobulina beta-2/sangre
4.
Rev. méd. Chile ; 135(9): 1111-1117, sept. 2007. graf, tab
Artículo en Español | LILACS | ID: lil-468198

RESUMEN

Background: Mortality rate records are the only data available in Chile about the prognosis of patients with multiple myeloma (MM). Aim To characterize clinical features, survival rate and factors related to mortality in cases with MM treated in six large medical centers in Chile. Material and Method: Retrospective analysis of demographic data, clinical features and survival rate records of patients with MM, collected between 1998 and 2002. Survival curves were generated and a multivariate analysis of factors associated to early mortality was carried out. Results: Data from 245patients aged 38 to 95years (129 women) was collected. Fifty two percent had an IgG myeloma, 25 percent had and IgA and 6.1 percent had light chains myeloma. According to Durie and Salmon staging system, 8,2 percent were in Stage 112.6 percent in Stage II, 60.5 percent in Stage III and in 18.8 percent the information about staging was not available. Fifty percent had an hemoglobin level below 10 g/dL, 30 percent had a serum creatinine over 2 mg/dL and 28 percent had a serum calcium level over 10.5 mg/dL. Median survival was 33 months. Twenty percent of patients died within the first six months after diagnosis (early mortality). Predictive factors for early mortality were male sex, thrombocytopenia, anemia, renal failure, hypercalcemia, a beta2-microglobulin >5.5 mg/L and a serum albumin level <3.5 g/dL. There was a correlation between the number of bad prognosis factors present and the probability of early mortality. Conclusions: This group of Chilean patients with MM presented a short survival time, and 20 percent died within the first six months after diagnosis. More than a half of cases were diagnosed at an advanced stage (Durie and Salmon Stage III). Several factors were associated to early mortality, two of which (beta 2-microglobulin and serum albumin), are included in the new International Staging System for MM.


Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/mortalidad , Insuficiencia Renal , Anemia/complicaciones , Chile/epidemiología , Métodos Epidemiológicos , Hipercalcemia/complicaciones , Mieloma Múltiple/inmunología , Mieloma Múltiple/patología , Estadificación de Neoplasias , Pronóstico , Albúmina Sérica/análisis , Factores Sexuales , Trombocitopenia/complicaciones , Factores de Tiempo , /sangre
6.
Rev. chil. obstet. ginecol ; 60(2): 118-24, 1995. tab
Artículo en Español | LILACS | ID: lil-162443

RESUMEN

Se presenta el caso clínico de una paciente de 37 años que cursa una leucemia mieloide aguda, durante el tratamiento cursó un embarazo, el cual es controlado en nuestro servicio en conjunto con hematología. La gestación se interrumpe a las 37 semanas mediante operación cesárea obteniéndose un producto vivo. Se revisa la asociación entre estas condiciones, su repercusión materno-fetal y el manejo obstétrico recomendado


Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Complicaciones Neoplásicas del Embarazo/terapia , Leucemia Mieloide Aguda/complicaciones , Antineoplásicos/administración & dosificación , Antibacterianos/administración & dosificación , Trabajo de Parto Inducido/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...